Anuh Pharma Limited has informed the Exchange regarding 'Granting Authorization To Key Managerial Personnel For Determination Of Materiality Of Events.'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma Limited reported FY2025-26 results with revenue from operations growing 16.6% to ₹77,165.74 Lakhs from ₹66,151.49 Lakhs in the prior year. However, Profit After Tax declined 13.3% to ₹4,104.61 Lakhs versus ₹4,735.19 Lakhs. EBITDA for the year stood at ₹6,607.59 Lakhs with margin compression from 10.64% to 8.56%. The company received an unmodified (clean) audit opinion from Jayantilal Thakkar & Co. The Board recommended a dividend of ₹1.50 per equity share (30% payout on face value), subject to shareholder approval at the August 2026 AGM. Nine promoter group members (totaling 0.95% shareholding) have requested reclassification to public category. The company also appointed new Internal Auditors M/s RMJ & Associates LLP for FY2026-27.
While revenue growth demonstrates business expansion, the decline in profitability and EBITDA margin compression are concerning signals for investors. The clean audit opinion provides confidence in financial reporting integrity. The dividend announcement offers some investor回报.